Articles in Scholarly Journals [Incomplete List]

1. Cancer-associated immune-mediated syndromes: Pathogenic values and clinical implementation
   Biomedicine & Pharmacotherapy, vol. 61, no. 6, pp. 323–337, 2007
2. Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease
   Journal of Autoimmunity, vol. 29, no. 2-3, pp. 106–115, 2007
3. Intracellular trafficking of ß2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome
   Journal of Autoimmunity, vol. 29, no. 2-3, pp. 164–173, 2007
4. Different pattern of HSP47 expression in skeletal muscle of patients with neuromuscular diseases
   Neuromuscular Disorders, vol. 17, no. 3, pp. 221–226, 2007
5. Elevated Serum sFlt-1/Ang-2 Ratio in Women with Preeclampsia
   Nephron Clinical Practice, vol. 106, no. 1, pp. c43–c50, 2007
6. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis
   The Journal of Lipid Research, vol. 48, no. 4, pp. 768–781, 2007
7. Determination of Oxidized Low-Density Lipoproteins (ox-LDL) versus ox-LDL/beta2GPI Complexes for the Assessment of Autoimmune-Mediated Atherosclerosis
   Annals of the New York Academy of Sciences, vol. 1109, no. 1, pp. 303–310, 2007
8. Antiphospholipid Antibodies in Patients with Coronary Artery Disease: New Cardiac Risk Factors?
   Annals of the New York Academy of Sciences, vol. 1108, no. 1, pp. 466–474, 2007
9. Subclinical Atherosclerosis in Primary Antiphospholipid Syndrome
   Annals of the New York Academy of Sciences, vol. 1108, no. 1, pp. 475–480, 2007
10. Atherogenic Antiphospholipid Antibodies in Antiphospholipid Syndrome
    Annals of the New York Academy of Sciences, vol. 1108, no. 1, pp. 489–496, 2007
11. Chronic Infections and Atherosclerosis
    Annals of the New York Academy of Sciences, vol. 1108, no. 1, pp. 594–602, 2007
12. Postinfectious immunodeficiency and autoimmunity: pathogenic and clinical values and implications
    Expert Review of Clinical Immunology, vol. 3, no. 3, pp. 323–331, 2007
13. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis
    Lupus, vol. 15, no. 2, pp. 80–86, 2006
14. Atherogenic oxidized low-density lipoprotein/ß₂-glycoprotein I (oxLDL/ß₂GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome
    Lupus, vol. 15, no. 7, pp. 478–483, 2006
15. Antibodies against ß 2 -glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome
    Clinical and Developmental Immunology, vol. 13, no. 1, pp. 1–9, 2006
16. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis
    Progress in Lipid Research, vol. 45, no. 6, pp. 466–486, 2006
17. Accelerated Atheroma in the Antiphospholipid Syndrome
    Rheumatic Disease Clinics of North America, vol. 32, no. 3, pp. 537–551, 2006
18. MRI studies of spinal visceral larva migrans syndrome
    Journal of the Neurological Sciences, vol. 249, no. 1, pp. 7–12, 2006
19. Significance of valine/leucine247 polymorphism of ?2-glycoprotein I in antiphospholipid syndrome: Increased reactivity of anti-?2-glycoprotein I autoantibodies to the valine247 ?2-glycoprotein I variant
    Arthritis & Rheumatism, vol. 52, no. 1, pp. 212–218, 2005
20. Increase of Serum Angiopoietin-2 During Pregnancy Is Suppressed in Women With Preeclampsia
    American Journal of Hypertension, vol. 18, no. 9, pp. 1181–1188, 2005
21. From animal models to human genetics: research on the induction and pathogenicity of autoantibodies
    Autoimmunity Reviews, vol. 4, no. 3, pp. 178–187, 2005
22. Research around ß2-glycoprotein I: A major target for antiphospholipid antibodies
    Autoimmunity, vol. 38, no. 5, pp. 377–381, 2005
23. Characterization of a murine anti-laminin-1 monoclonal antibody (AK8) produced by immunization with mouse-derived laminin-1
    Clinical and Developmental Immunology, vol. 12, no. 1, pp. 67–73, 2005
24. Antigenic structures recognized by anti- 2-glycoprotein I auto-antibodies
    International Immunology, vol. 17, no. 12, pp. 1533–1542, 2005
25. Oxidized Low-Density Lipoprotein/ 2-Glycoprotein I Complexes and Autoantibodies in Patients with Type 2 Diabetes Mellitus
    Annals of the New York Academy of Sciences, vol. 1051, no. 1, pp. 97–103, 2005
26. Pregnancy Loss and Endometriosis: Pathogenic Role of Anti-Laminin-1 Autoantibodies
    Annals of the New York Academy of Sciences, vol. 1051, no. 1, pp. 174–184, 2005
27. OxLDL/ 2GPI Complexes and Autoantibodies in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, and Antiphospholipid Syndrome: Pathogenic Implications for Vascular Involvement
    Annals of the New York Academy of Sciences, vol. 1051, no. 1, pp. 313–322, 2005
28. The Role of Innate and Adaptive Immunity to Oxidized Low-Density Lipoprotein in the Development of Atherosclerosis
    Annals of the New York Academy of Sciences, vol. 1051, no. 1, pp. 442–454, 2005
29. Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases
    Circulation, vol. 112, no. 21, pp. 3337–3347, 2005
30. Binding of  2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells
    Blood, vol. 105, no. 4, pp. 1552–1557, 2005
31. Lymphocyte subpopulations and intima media thickness in primary antiphospholipd syndrome
    Lupus, vol. 14, no. 10, pp. 809–813, 2005
32. Oxidized LDL/β₂-glycoprotein I complexes: new aspects in atherosclerosis
    Lupus, vol. 14, no. 9, pp. 736–741, 2005
33. Intravenous Immunoglobulin and Atherosclerosis
    Clinical Reviews in Allergy & Immunology, vol. 29, no. 3, pp. 311–320, 2005
34. Oxidized Low-Density Lipoprotein/b 2 -Glycoprotein I Complexes and Autoantibodies to oxLig-1/b 2 -Glycoprotein I in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome
    American Journal of Clinical Pathology, vol. 121, no. 3, pp. 426–436, 2004
35. Nicked ?2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis
    Blood, vol. 103, no. 10, pp. 3766–3772, 2004
36. Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective?
    Circulation, vol. 110, no. 17, pp. 2552–2558, 2004
37. Clinical Significance of Serum Oxidized Low-Density Lipoprotein/β₂-Glycoprotein I Complexes in Patients with Chronic Renal Diseases
    Nephron Clinical Practice, vol. 98, no. 1, pp. c15–c24, 2004
38. Are Oxidized LDL/β2-glycoprotein I Complexes Pathogenic Antigens in Autoimmune-mediated Atherosclerosis?
    Clinical and Developmental Immunology, vol. 11, no. 2, pp. 103–111, 2004
39. Anti-laminin-1 Autoantibodies, Pregnancy Loss and Endometriosis
    Clinical and Developmental Immunology, vol. 11, no. 3-4, pp. 261–266, 2004
40. IgG Autoantibodies against β2-Glycoprotein I Complexed with a Lipid Ligand Derived from Oxidized Low-Density Lipoprotein are Associated with Arterial Thrombosis in Antiphospholipid Syndrome
    Clinical & Developmental Immunology, vol. 10, no. 2, pp. 203–211, 2003
41. An association of IgG anti-laminin-1 autoantibodies with endometriosis in infertile patients
    Human Reproduction, vol. 18, no. 3, pp. 544–549, 2003
42. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen
    The Journal of Lipid Research, vol. 44, no. 4, pp. 716–726, 2003
43. Journal of Assisted Reproduction and Genetics, vol. 20, no. 2, pp. 53–57, 2003
44. Immunization of Naive Mice with Mouse Laminin-1 Affected Pregnancy Outcome in a Mouse Model
    American Journal of Reproductive Immunology, vol. 50, no. 2, pp. 159–165, 2003
45. Hybridomas Expressing gammadelta T-Cell Receptors Respond to Cardiolipin and beta2-Glycoprotein 1 (Apolipoprotein H)
    Scandinavian Journal of Immunology, vol. 58, no. 3, pp. 374–381, 2003
46. Atherogenic autoantigen: oxidized LDL complexes with ?2-glycoprotein I
    Immunobiology, vol. 207, no. 1, pp. 17–22, 2003
47. Anti-idiotypes to Oxidized LDL Antibodies in Intravenous Immunoglobulin Preparations--Possible Immunomodulation of Atherosclerosis
    Autoimmunity, vol. 36, no. 2, pp. 91–97, 2003
48. Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome
    Lupus, vol. 12, no. 7, pp. 550–554, 2003
49. Autoantibody-mediated atherosclerosis
    Autoimmunity Reviews, vol. 1, no. 6, pp. 348–353, 2002
50. Anti-β 2 -Glycoprotein I Autoantibodies and Atherosclerosis
    International Reviews Of Immunology, vol. 21, no. 1, pp. 51–66, 2002
51. The Orientation of ß2GPI on the Plate is Important for the Binding of Anti-ß2GPI Autoantibodies by ELISA
    Journal of Autoimmunity, vol. 18, no. 4, pp. 289–297, 2002
52. omega-Carboxyl variants of 7-ketocholesteryl esters are ligands for beta2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages
    The Journal of Lipid Research, vol. 43, no. 9, pp. 1486–1495, 2002
53. Anti-beta2-glycoprotein I antibodies in children with atopic dermatitis
    International Immunology, vol. 14, no. 7, pp. 823–830, 2002
54. Analysis of Epitopes of Mouse Monoclonal Antibodies against Human Alpha-Fetoprotein
    Tumor Biology, vol. 22, no. 4, pp. 254–261, 2001
55. Expression of vascular endothelial growth factor in tuberculous meningitis
    Journal of the Neurological Sciences, vol. 186, no. 1-2, pp. 75–79, 2001
56. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis
    Journal of the Neurological Sciences, vol. 173, no. 1, pp. 45–52, 2000
57. ß2-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis
    Atherosclerosis, vol. 152, no. 2, pp. 337–346, 2000
58. ß2-glycoprotein I–anti-ß2-glycoprotein I Interaction
    Journal of Autoimmunity, vol. 15, no. 2, pp. 97–100, 2000
59. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant
    Arthritis & Rheumatism, vol. 43, no. 9, pp. 1982–1993, 2000
60. Proteolytic cleavage of beta2-glycoprotein I: reduction of antigenicity and the structural relationship
    International Immunology, vol. 12, no. 8, pp. 1183–1192, 2000
61. Accelerated atheroma and anti β2-glycoprotein I antibodies
    Lupus, vol. 9, no. 3, pp. 210–216, 2000
62. Modulation of T Cell Function by Alpha-Fetoprotein: An in vivo Study on Porcine Thyroid Peroxidase-Induced Experimental Autoimmune Thyroiditis in Transgenic Mice Producing Human Alpha-Fetoprotein
    Tumor Biology, vol. 20, no. 3, pp. 162–171, 1999
63. ?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
    Arthritis & Rheumatism, vol. 42, no. 1, pp. 167–174, 1999
64. A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies
    Arthritis & Rheumatism, vol. 42, no. 11, pp. 2461–2470, 1999
65. Use of various methods for anticardiolipin detection in the updated American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: Comment on the letter by Hochberg
    Arthritis & Rheumatism, vol. 41, no. 7, pp. 1326–1327, 1998
66. A 50-kDa variant form of human surfactant protein D
    European Respiratory Journal, vol. 12, no. 5, pp. 1147–1155, 1998
67. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human beta 2-glycoprotein I
    International Immunology, vol. 9, no. 6, pp. 913–921, 1997
68. DNA-alginate complex recognized by autoantibodies against DNA
    International Journal of Biological Macromolecules, vol. 20, no. 1, pp. 75–77, 1997
69. Antibodies to ß2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus
    Arthritis & Rheumatism, vol. 39, no. 9, pp. 1466–1474, 1996
70. Relationship of microparticles with ?2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura
    Annals of Hematology, vol. 70, no. 1, pp. 25–30, 1995
71. Clinical significance of $beta;2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: Correlation with conventional antiphospholipid antibody detection systems
    American Journal of Obstetrics and Gynecology, vol. 172, no. 3, pp. 926–931, 1995
72. Systemic lupus erythematosus and anticardiolipin antibodies in Klinefelter's syndrome
    Lupus, vol. 4, no. 3, pp. 236–238, 1995
73. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface
    Journal of Experimental Medicine, vol. 179, no. 2, pp. 457–462, 1994
74. Enzyme-linked immunosorbent assay for human pulmonary surfactant protein D
    Journal of Immunological Methods, vol. 173, no. 2, pp. 157–164, 1994
75. ß2-GPI-dependent and independent binding of anticardiolipin antibodies in patients with recurrent spontaneous abortions
    Journal of Clinical Laboratory Analysis, vol. 8, no. 5, pp. 255–259, 1994
76. ß2-Glycoprotein i reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome
    Arthritis & Rheumatism, vol. 37, no. 10, pp. 1453–1461, 1994
77. What is the "true" antigen for anticardiolipin antibodies?
    The Lancet, vol. 337, no. 8742, pp. 671–672, 1991
78. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
    The Lancet, vol. 336, no. 8708, pp. 177–178, 1990